[1]徐晓林,朱争艳,经 翔.肝细胞癌患者射频消融前后的免疫状态研究进展[J].介入放射学杂志,2017,(01):87-91.
　XU Xiao- lin,ZHU Zheng- yan,JING Xiang.The immune state in patients with hepatocellular carcinoma before and after radiofrequency ablation treatment： recent progress in research[J].journal interventional radiology,2017,(01):87-91.
点击复制

肝细胞癌患者射频消融前后的免疫状态研究进展 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年01期
页码:
87-91
栏目:
综述
出版日期:
2017-01-25

文章信息/Info

Title:
The immune state in patients with hepatocellular carcinoma before and after radiofrequency ablation treatment： recent progress in research
作者:
徐晓林;  朱争艳;  经 翔
Author(s):
XU Xiao- lin;  ZHU Zheng- yan;  JING Xiang
Third Central Clinical College of Tianjin Medical University， Tianjin 300170， China
关键词:
【关键词】 肝细胞癌;  射频消融;  免疫
文献标志码:
A
摘要:
【摘要】 射频消融（RFA）治疗肝细胞癌（HCC）后，肿瘤细胞发生凝固性坏死与凋亡，产生原位肿瘤抗原，直接或间接激发机体固有免疫及适应性免疫反应，帮助逆转机体免疫抑制状态。本文主要对RFA治疗HCC引起的局部及全身性免疫反应、适应性免疫及固有免疫及其对细胞因子的调节发挥的作用进行综述，进而对RFA治疗HCC后的机体免疫改变进行阐明。

参考文献/References:

［1］ Torre LA， Bray F， Siegel RL， et al. Global cancer statistics， 2012［J］. CA Cancer J Clin， 2015， 65： 87- 108.
［2］ Hatzaras I， Bischof DA， Fahy B， et al. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma［J］. Ann Surg Oncol， 2014， 21： 758- 766.
［3］ Tiong L， Maddern GJ. Systematic review and meta- analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma［J］. Br J Surg， 2011， 98： 1210- 1224.
［4］ Nobuoka D， Motomura Y， Shirakawa HA， et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican- 3 peptide- specific cytotoxic T lymphocytes［J］. Int J Oncol， 2012， 40： 63- 70.
［5］ Napoletano C， Taurino F， Biffoni M， et al. RFA strongly modulates the immune system and anti- tumor immune responses in metastatic liver patients［J］. Int J Oncol， 2008， 32： 481- 490.
［6］ Guan HT， Wang J， Yang M， et al. Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients［J］. Chin Med J （Engl）， 2013， 126： 3651- 3655.
［7］ Zerbini A， Pilli M， Penna A， et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor- specific T- cell responses［J］. Cancer Res， 2006， 66： 1139- 1146.
［8］ 韩聚强， 范公忍， 任永强， 等． 不同微创介入治疗原发性肝癌对机体T细胞免疫功能的影响［J］． 介入放射学杂志， 2014， 23： 218- 221．
［9］ Ahmed M， Kumar G， Moussa M， et al. Hepatic radiofrequency ablation- induced stimulation of distant tumor growth is suppressed by c- Met inhibition［J］. Radiology， 2016， 279： 103- 117.
［10］ Rozenblum N， Zeira E， Bulvik B， et al. Radiofrequency ablation： inflammatory changes in the periablative zone can induce global organ effects， including liver regeneration［J］. Radiology， 2015， 276： 416- 425.
［11］ Rozenblum N， Zeira E， Scaiewicz V， et al. Oncogenesis： an “off- target” effect of radiofrequency ablation［J］. Radiology， 2015， 276： 426- 432.
［12］ Chen KJ， Zhou L， Xie HY， et al. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection［J］. Med Oncol， 2012， 29： 1817- 1826.
［13］ Flecken T， Schmidt N， Hild S， et al. Immunodominance and functional alterations of tumor- associated antigen- specific CD8+ T- cell responses in hepatocellular carcinoma［J］. Hepatology， 2014， 59： 1415- 1426.
［14］ Hernandez- Gea V， Toffanin S， Friedman SL， et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma［J］. Gastroenterology， 2013， 144： 512- 527.
［15］ Witkowski M， Spangenberg HC， Neumann- Haefelin C， et al. Lack of ex vivo peripheral and intrahepatic α- fetoprotein- specific CD4+ responses in hepatocellular carcinoma［J］. Int J Cancer， 2011， 129： 2171- 2182.
［16］ Fu J， Xu D， Liu Z， et al. Increased regulatory T cells correlate with CD8 T- cell impairment and poor survival in hepatocellular carcinoma patients［J］. Gastroenterology， 2007， 132： 2328- 2339.
［17］ Pedroza- Gonzalez A， Verhoef C， Ijzermans JN， et al. Activated tumor- infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer［J］. Hepatology， 2013， 57： 183- 194.
［18］ Song S， Yuan P， Li P， et al. Dynamic analysis of tumor- associated immune cells in DEN- induced rat hepatocellular carcinoma［J］. Int Immunopharmacol， 2014， 22： 392- 399.
［19］ Huang Y， Wang F， Wang Y， et al. Intrahepatic interleukin- 17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma［J］. J Gastroenterol Hepatol， 2014， 29： 851- 859.
［20］ Zhang B， Jia H， Liu J， et al. Depletion of regulatory T cells facilitates growth of established tumors： a mechanism involving the regulation of myeloid- derived suppressor cells by lipoxin A4［J］. J Immunol， 2010， 185： 7199- 7206.
［21］ Gao HJ， Zhang YJ， Liang HH， et al. Radiofrequency ablation does not induce the significant increase of CD4+ CD25+ Foxp3+ regulatory T cells compared with surgical resection in Hepal- 6 tumor model［J］. Arch Immunol Ther Exp （Warsz）， 2013， 61： 333- 340.
［22］ Kakumu S， Ito S， Ishikawa T， et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection［J］. J Gastroenterol Hepatol， 2000， 15： 431- 436.
［23］ Kitahara M， Mizukoshi E， Nakamoto Y， et al. Efficient generation of highly immunocompetent dendritic cells from peripheral blood of patients with hepatitis C virus- related hepatocellular carcinoma［J］. Int Immunopharmacol， 2014， 21： 346- 353.
［24］ Pardee AD， Shi J， Butterfield LH. Tumor- derived α- fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells［J］. J Immunol， 2014， 193： 5723- 5732.
［25］ Dromi SA， Walsh MP， Herby S， et al. Radiofrequency ablation induces antigen- presenting cell infiltration and amplification of weak tumor- induced immunity［J］. Radiology， 2009， 251： 58- 66.
［26］ 戴维德， 范智慧， 陈敏华， 等． 正常大鼠肝脏射频消融前后外周血树突状细胞的变化及意义［J］． 中国介入影像与治疗学， 2006， 3： 137- 140．
［27］ 范智慧， 陈敏华， 戴维德， 等． 射频消融治疗前后大鼠树突状细胞的变化［J］． 中国医学影像技术， 2006， 22： 1143- 1146．
［28］ Zerbini A， Pilli M， Fagnoni F， et al. Increased immunostimulatory activity conferred to antigen- presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation［J］. J Immunother， 2008， 31： 271- 282.
［29］ Ali MY， Grimm CF， Ritter M， et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma［J］. J Hepatol， 2005， 43： 817- 822.
［30］ Sha WH， Zeng XH， Min L. The correlation between NK cell and liver function in patients with primary hepatocellular carcinoma［J］. Gut Liver， 2014， 8： 298- 305.
［31］ Cheung PF， Yip CW， Ng LW， et al. Restoration of natural killer activity in hepatocellular carcinoma by treatment with antibody against granulin- epithelin precursor［J］. Oncoimmunology， 2015， 4： e1016706.
［32］ Ramzan M， Sturm N， Decaens T， et al. Liver- infiltrating CD8+ lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus- related hepatocellular carcinoma［J］. Liver Int， 2016， 36： 434- 444.
［33］ Mao Y， Sarhan D， Steven A， et al. Inhibition of tumor- derived prostaglandin- e2 blocks the induction of myeloid- derived suppres- sor cells and recovers natural killer cell activity［J］. Clin Cancer Res， 2014， 20： 4096- 4106.
［34］ Jang JW， Oh BS， Kwon JH， et al. Serum interleukin- 6 and C- reactive protein as a prognostic indicator in hepatocellular carcinoma［J］. Cytokine， 2012， 60： 686- 693.
［35］ Lee IC， Huang YH， Chau GY， et al. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments［J］. Int J Cancer， 2013， 133： 2895- 2902.
［36］ Wubetu GY， Utsunomiya T， Ishikawa D， et al. High STAT4 expression is a better prognostic indicator in patients with hepatocellular carcinoma after hepatectomy［J］. Ann Surg Oncol， 2014， 21： S721- S728.
［37］ Kao JT， Feng CL， Yu CJ， et al. IL- 6， through p- STAT3 rather than p- STAT1， activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients： a cohort study［J］. BMC Gastroenterol， 2015， 15： 50.
［38］ Moran DM， Mattocks MA， Cahill PA， et al. Interleukin- 6 mediates G0/G1 growth arrest in hepatocellular carcinoma through a STAT 3- dependent pathway［J］. J Surg Res， 2008， 147： 23- 33.
［39］ Cho HJ， Kim SS， Ahn SJ， et al. Low serum interleukin- 6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment［J］. Cytokine， 2015， 73： 245- 252.
［40］ Beckebaum S， Zhang X， Chen X， et al. Increased levels of interleukin- 10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets［J］. Clin Cancer Res， 2004， 10： 7260- 7269.
［41］ Chau GY， Wu CW， Lui WY， et al. Serum interleukin- 10 but not interleukin- 6 is related to clinical outcome in patients with resectable hepatocellular carcinoma［J］. Ann Surg， 2000， 231： 552- 558.
［42］ Saxena R， Chawla YK， Verma I， et al. Association of interleukin- 10 with hepatitis B virus（HBV） mediated disease progression in Indian population［J］. Indian J Med Res， 2014， 139： 737- 745.
［43］ Hansler J， Wissniowski TT， Schuppan D， et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radiofrequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases［J］. World J Gastroenterol， 12： 3716- 3721.
［44］ Erinjeri JP， Thomas CT， Samoilia A， et al. Image- guided thermal ablation of tumors increases the plasma level of interleukin- 6 and interleukin- 10［J］. J Vasc Interv Radiol， 2013， 24： 1105- 1112.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(01):177.
[2]蒲红.上海市第二届射频消融疑难病例研讨会纪要[J].介入放射学杂志,1997,(01):63.
[3]蒲红,尹炯,王咏梅,等.显性间隔房室旁路的射频消融[J].介入放射学杂志,1997,(02):104.
[4]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(01):333.
[5]罗荣光,黄金华.肿瘤射频消融：电极的类型和消融灶的特点[J].介入放射学杂志,2011,(02):159.
　LUO Rong-guang,HUANG Jin-hua..Radiofrequency ablation of tumors: the relationship between the electrode type and the feature of ablated zone[J].journal interventional radiology,2011,(01):159.
[6]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(01):206.
[7]程洪涛,郭晨阳,黎海亮,等.ＴＡＣＥ联合射频消融治疗原发性肝癌疗效的影响因素分析[J].介入放射学杂志,2012,(03):216.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ＣＴｇｕｉｄｅｄ ｐｅｒｃｕｔａｎｅｏｕｓ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｔｈｅ ｔｒｅａｔｍｅｎｔ ｏｆ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａｎ ａｎａｌｙｓｉｓ ｏｆ ｆａｃｔｏｒｓ ａｆｆｅｃｔｉｎｇ ｔｈｅ ｔｈｅｒａｐｅｕｔｉｃ ｒｅｓｕｌｔ [J].journal interventional radiology,2012,(01):216.
[8]姚红响,陈根生,诸葛英,等.肝动脉化疗栓塞联合ＣＴ引导射频消融序贯治疗中小肝癌的临床应用[J].介入放射学杂志,2012,(04):301.
　,,et al.Ｓｅｑｕｅｎｔｉａｌ ｔｒｅａｔｍｅｎｔ ｗｉｔｈ ＴＡＣＥ ａｎｄ ＣＴｇｕｉｄｅｄ ＲＦＡ ｆｏｒ ｓｍａｌｌ ａｎｄ ｍｏｄｅｒａｔｅ ｓｉｚｅｄ ＨＣＣ [J].journal interventional radiology,2012,(01):301.
[9]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗３０例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｍａｓｓｉｖｅ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａ ｃｌｉｎｉｃａｌ ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ [J].journal interventional radiology,2012,(01):322.
[10]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(01):469.
[11]赵 松,陈学春,龙清云,等. 经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J].介入放射学杂志,2013,(11):908.
　ZHAO Song,CHEN Xue? chun,LONG Qing? yun,et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma： a systematic review and Meta analysis[J].journal interventional radiology,2013,(01):908.
[12]王晓维,付守忠,戴 锋,等.肝动脉栓塞化疗联合射频消融与联合微波消融治疗原发性肝癌的疗效和安全性比较 [J].介入放射学杂志,2016,(08):673.
　WANG Xiao-wei,FU Shou-zhong,DAI Feng,et al.The curative effect and safety in treating primary hepatocellular carcinoma: comparison between TACE plus radiofrequency ablation and TACE plus microwave ablation [J].journal interventional radiology,2016,(01):673.
[13]郝美君,刘 凯,郭向华,等.射频消融亚致死性温度对肝癌干细胞的影响 [J].介入放射学杂志,2017,(07):636.
　HAO Meijun,LIU Kai,GUO Xianghua,et al.The effect of radiofrequency ablation with sublethal temperature on the stem cells of hepatocellular carcinoma[J].journal interventional radiology,2017,(01):636.
[14]刘 毅,卓 琳,朱 蓓,等.肝动脉化疗栓塞联合经皮消融治疗肝细胞癌疗效的meta分析 [J].介入放射学杂志,2017,(09):830.
　LIU Yi,ZHUO Lin,ZHU Bei,et al.Transcatheter arterial chemoembolization in combination with percutaneous ablation therapy for the treatment of hepatocellular carcinoma： a meta- analysis[J].journal interventional radiology,2017,(01):830.
[15]龙 江,赵 鹏,杨晓珍,等.射频消融治疗中等肝细胞癌5年预后及影响因素分析 [J].介入放射学杂志,2019,28(04):343.
　LONG Jiang,ZHAO Peng,YANG Xiaozhen,et al.Radiofrequency ablation for the treatment of medium- sized hepatocellular carcinomas： analysis of 5- year prognosis and influencing factors[J].journal interventional radiology,2019,28(01):343.
[16]彭建扬,翁志成,吴伟达,等.3.0T MR引导下肝细胞癌射频消融术的可行性研究[J].介入放射学杂志,2019,28(11):1062.
　PENG Jianyang,WENG Zhicheng,WU Weida,et al.Feasibility study of 3.0T MR-guided radiofrequency ablation for hepatocellular carcinoma[J].journal interventional radiology,2019,28(01):1062.
[17]季亚香,奚 静,刘春艳,等.基于天冬氨酸转氨酶-血小板计数比的列线图模型对肝细胞癌射频消融治疗后复发的预测价值[J].介入放射学杂志,2024,33(01):39.
　JI Yaxiang,XI Jing,LIU Chunyan,et al.The predictive value of a nomogram model based on aspartate aminotransferase-platelet ratio index for hepatocellular carcinoma recurrence after radiofrequency ablation[J].journal interventional radiology,2024,33(01):39.

备注/Memo

备注/Memo:
（收稿日期：２０１6-０5-０3）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2017-01-17